UNSPSC 51191517: Isosorbide

This classification denotes a vasodilating agent with the molecular formula C6H10O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WXR179L51S, chemically known as 1,4-dianhydrosorbitol but generally known as isosorbide, which bears US NIH Compound Identifier 12597. European Medicines Agency schedules Isosorbide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08334MIG.

UNSPSC 51191517 Isosorbide, a Commodity code, captures state and local procurement of specific pharmaceutical products for emergency medical services, pharmacy benefit programs, and institutional healthcare distribution. State and local governments buy isosorbide and related medications under this code as part of broader advanced life support (ALS) medication programs, generic pharmaceutical supply agreements, and pharmacy benefit management initiatives. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances representing multiple state and local jurisdictions. The work spans both direct medication procurement for emergency medical services and manufacturer-to-wholesaler supply agreements supporting multistate pharmaceutical distribution networks.

Recent activity centers on Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 seeking ALS medications including epinephrine, adenosine, labetalol, and diltiazem for Tampa Fire Rescue, with a response date of April 8, 2026 and an estimated contract value of $40,000; the procurement includes a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, soliciting information about direct contracting and outcomes-based pricing models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026; awarded vendors supply through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness. All three opportunities require compliance with FDA requirements, Good Manufacturing Practices, Drug Supply Chain Security Act standards, and OSHA Hazard Communication Standards.